Background
Step 1 | Step 2 | Step 3 (Select one) | Step 4 (Add one or more) |
---|---|---|---|
SABA | Low dose ICS | A. Medium-or high dose ICS | A. Medium-or high dose ICS + LABA |
B. Low dose ICS + LABA | B. LTRA | ||
C. Low dose ICS + LTRA | C. Theophylline | ||
D. Low dose ICS + Theophylline |
Methods
Search strategy
Inclusion and exclusion criteria
Selection
Data extraction
Quality assessment
Study ID[ref] | 1 [19] | 2 [20] | 3 [21] | 4 [22] | 5 [23] | 6 [24] | 7 [25] | 8 [26] | 9 [7] | 10 [9] | 11 [27] | 12 [28] | 13 [29] | 14 [30] | 15 [31] | 16 [8] | 17 [32] | 18 [33] | 19 [6] | 20 [34] | 21 [10] | 22 [35] | 23 [36] | Y | N | ? |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sequence generation
|
?
|
?
|
?
|
Y
|
?
|
Y
|
?
|
?
|
Y
|
?
|
?
|
?
|
Y
|
Y
|
?
|
?
|
Y
|
?
|
Y
|
?
|
Y
|
?
|
Y
|
9
|
0
|
14
|
Allocation concealment
|
?
|
?
|
Y
|
Y
|
?
|
?
|
?
|
?
|
Y
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
Y
|
?
|
?
|
?
|
?
|
?
|
Y
|
5
|
0
|
18
|
Appropriate blinding of participants
|
?
|
N
|
Y
|
N
|
?
|
?
|
?
|
Y
|
N
|
Y
|
?
|
?
|
?
|
?
|
?
|
?
|
Y
|
?
|
Y
|
?
|
?
|
N
|
Y
|
6
|
4
|
13
|
Appropriate blinding of outcome assessors
|
?
|
Y
|
Y
|
N
|
?
|
?
|
?
|
Y
|
?
|
Y
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
N
|
Y
|
5
|
2
|
16
|
Appropriate blinding of physician
|
?
|
?
|
Y
|
N
|
?
|
?
|
?
|
Y
|
?
|
Y
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
N
|
Y
|
4
|
2
|
17
|
Registration of loss to follow-up
|
Y
|
Y
|
?
|
?
|
Y
|
Y
|
?
|
?
|
Y
|
Y
|
Y
|
Y
|
Y
|
Y
|
Y
|
?
|
?
|
Y
|
?
|
Y
|
Y
|
Y
|
Y
|
16
|
0
|
7
|
Way missing values were dealt with
|
?
|
?
|
?
|
Y
|
?
|
?
|
?
|
?
|
Y
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
Y
|
Y
|
?
|
?
|
?
|
?
|
?
|
4
|
0
|
19
|
Compliance checked
|
Y
|
?
|
?
|
Y
|
Y
|
?
|
?
|
?
|
Y
|
?
|
?
|
Y
|
Y
|
Y
|
?
|
Y
|
?
|
Y
|
?
|
?
|
Y
|
?
|
Y
|
11
|
0
|
12
|
Selective reporting
|
?
|
?
|
?
|
?
|
?
|
N
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
?
|
0
|
1
|
22
|
Total times “Yes”
|
2
|
2
|
4
|
4
|
2
|
2
|
0
|
3
|
5
|
4
|
1
|
3
|
3
|
3
|
1
|
1
|
4
|
3
|
2
|
1
|
3
|
1
|
7
| |||
Overall score Y/N/?
|
60
|
9
|
138
|
Statistical analysis
Results
Studies and patients
Outcome measurements
Scale of FEV1
| Outcome summary measure | Reference number of study reporting summary measure at T0
a
| Reference number of study reporting summary measure at Te
b
|
---|---|---|---|
Liter
| Mean | 13, 15, 19 | |
Mean change | 10, 14, 18 | ||
Mean + SE or SD | 8, 10, 11, 16, 18, 22, 23 | 8, 16 | |
Mean change + SE or SD | 23 | ||
Mean + range | 14, 15, 16, 19 | 16 | |
P-value versus another arm | 10, 14, 15, 18, 19, 23 | ||
Difference between arms + 95%CI | 13, 23 | ||
% of predicted
| Mean | 13 | |
Mean change | 11, 12, 18 | ||
Mean + SE or SD | 2, 3, 5, 6, 7, 9, 10, 11, 16, 17, 18, 20, 21, 22 | 2, 3, 6, 7, 9, 16, 17, 20 | |
Mean change + SE or SD | |||
Mean + range | 12, 13, 14, 15, 16, 17, 19 | 16 | |
P-value versus another arm | 11, 12, 18 | ||
Difference between arms + 95%CI | 13, 17 |
Attempts to salvage the situation
Descriptive findings of key trials
Step 3A versus 3B
Study | 3A-3B | 3B-4A | ||||
---|---|---|---|---|---|---|
Outcome | Gappa[32] Differences between groups (95%CI) | Bisgaard[6] Differences between groups (p) | De Blic[36] Differences between groups (95%CI; p) | Tal[29] Differences between groups (95%CI) | Morice[30] Differences between groups (95%CI; p) | Pohunek[31] Differences between groups (p) |
Number of exacerbations | n.a. | n.d. | n.d. | n.a. | n.a. | n.a. |
Level of control | p=0.02a
| 9.8(0.047)b
| n.d. | n.d. | n.d. | n.d. |
Reliever medication use/reliever free daysc
| 8.7(1.2-16.3) | n.d. | 1.4(0.0-3.4; 0.025) | n.d. | n.d. | n.d. |
Symptom score (day&night) | n.d. | 0.27(0.024) | n.a. | n.d. | n.d. | n.d. |
nighttime awakening | n.a. | n.d. | n.d. | n.d. | n.d. | n.d. |
Quality of life | n.a. | n.a. | n.a. | n.a. | n.d. | n.d. |
Lung function (FEV1) | n.d. | n.d. | n.d. | 3.75(1.1-6.4)d
| n.a. | 0.08(<0.01)e & 0.06(<0.001)e
|
Hyperresponsiveness (PC20-FEV1) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
morning PEF | 6.1(1.8-10.4)d
| n.d. | 7.6(1.7-13.5)e
| 3.77(1.84-5.7)d
| 9.5(4.2-14.9; <0.001)e & 10.3(5.0-15.6; <0.001)e,f
| 15(<0.001)e & 6(<0.001)e,f
|